Skip to content
  • facebook.com
  • twitter.com
  • t.me
  • instagram.com
  • youtube.com
BioTechGrid BioTechGrid
  • Home
  • Biotechnology
  • Medical Technology
  • Research
  • Genetics
  • Press Releases
    • Business Wire
    • GlobeNewswire
    • PRNewswire
  • Contact
  • Home
  • Biotechnology
  • BMS CEO Boerner doesn’t ‘feel any compulsion to chase deals’ despite lack of M&A this year

BMS CEO Boerner doesn’t ‘feel any compulsion to chase deals’ despite lack of M&A this year

July 30, 2026Posted inBiotechnology

BMS may have been absent from the dealmaking spree of some of its Big Pharma peers this year, but that might not change anytime soon.

Post navigation

Previous Post
non-invasive-biomarkers-for-early-oral-cancer-detection-through-multiomics-approach Non-invasive biomarkers for early oral cancer detection through multiomics approach
Next Post
Latigo Reports Positive Phase IIb Data for Non-Opioid Acute Pain Candidate latigo-reports-positive-phase-iib-data-for-non-opioid-acute-pain-candidate

Recent Posts

  • Lightweight AI Reads Brain Tumor Scans and Knows When It Is Unsure
  • Blood Type Offers No Shield Against Common Skin Warts, Study Finds
  • New AI Framework Blends Infrared and Visible Images by Seeing Others and Focusing Itself
  • Sick Leeches Keep Their Microbial Diversity but Lose Their Microbial Stability
  • Brain Tumor Biomarker Survives Tough Test: MGMT Signal Holds After Batch Effect Scrutiny

Archives

  • October 2026
  • September 2026
  • August 2026
  • July 2026
  • September 2024
  • August 2024
  • March 2024
  • September 2023

Privacy Policy    Terms

Scroll to Top